GleamWall
中文EN

RNLXY Renalytix plc

Services-Medical Laboratories · OTC · SEC CIK 1811115 · Fiscal year ends 06/30

Financial factors as of 2024-03-31 (2024Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-40.2%
TTM net income YoY5.5%
TTM EPS YoY30.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin-1.6%
Operating margin-1,531.6%
Net margin-1,687.8%
FCF margin—
EBITDA margin-1,515.1%

Returns

ROE-1,073.2%
ROA-154.4%
ROIC (approx.)—
Asset turnover0.09x

Leverage & solvency

Liabilities / assets226.7%
Debt / equity—
Current ratio0.42x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio-27.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2025Q12024-09-302024Q4*2024-06-302024Q32024-03-312024Q22023-12-312024Q12023-09-302023Q4*2023-06-302023Q32023-03-312023Q22022-12-31
Income statement
Revenue$522,000$586,000$535,000$709,000$459,000$518,000$724,000$1.19M
Cost of revenue$422,000$550,000$601,000$480,000$502,000$673,000$603,000$711,000
Gross profit$100,000$36,000-$66,000$229,000-$43,000-$155,000$121,000$481,000
R&D expense$921,000$1.06M$2.22M$3.23M$2.79M$3.27M$3.94M$3.33M
SG&A expense$3.27M$4.50M$3.85M$5.34M$6.06M$6.51M$7.09M$6.81M
Operating income-$4.09M-$5.53M-$6.55M-$8.64M-$8.89M-$9.93M-$10.92M-$9.65M
Pretax income-$4.73M-$7.07M-$7.74M-$8.48M-$10.15M-$11.10M-$12.11M-$10.44M
Income tax$2,000$0$0$4,000$0$4,000-$1,000$0
Net income-$4.73M-$7.07M-$7.74M-$8.48M-$10.15M-$11.10M-$12.11M-$10.44M
EBITDA-$4.03M-$5.46M-$6.53M-$8.54M-$8.76M-$9.81M-$10.82M-$9.55M
EPS (basic)-0.04—-0.08-0.09-0.11—-0.14-0.14
EPS (diluted)-0.04—-0.08-0.09-0.11—-0.14-0.14
Weighted avg. shares (diluted)105.70M—97.65M97.27M94.77M—85.56M74.89M
Balance sheet
Cash & equivalents$909,000$4.68M$4.70M$5.62M$13.89M$24.68M$33.03M$23.82M
Receivables$902,000$722,000$554,000$1.37M$1.01M$776,000$747,000$820,000
Current assets$2.88M$6.12M$6.34M$8.25M$16.47M$26.88M$35.73M$26.60M
PP&E, net$202,000$216,000$230,000$576,000$944,000$1.03M$2.19M$2.29M
Intangibles$869,000$869,000$913,000$965,000$974,000$1.05M$1.09M$1.13M
Total assets$4.79M$7.97M$8.77M$11.28M$19.54M$30.63M$39.80M$30.66M
Current liabilities$12.01M$11.49M$14.99M$13.92M$15.17M$16.14M$14.68M$14.29M
Total liabilities$16.11M$15.83M$19.88M$19.23M$21.03M$23.66M$21.70M$21.77M
Shareholders' equity-$11.32M-$7.85M-$11.11M-$7.96M-$1.49M$6.97M$18.10M$8.88M
Shares outstanding165.93M154.37M119.92M99.93M93.78M93.78M93.78M74.89M
Cash flow statement
Operating cash flow-$3.84M-$7.83M-$4.86M-$7.92M-$9.50M-$8.63M-$10.10M-$8.23M
Capital expenditure—————$0$0$0
Free cash flow—————-$8.63M-$10.10M-$8.23M
Investing cash flow$23,000-$1,000-$3,000$0$0$59,000$5,000-$64,000
Financing cash flow$0$7.79M$4.03M-$507,000-$1.06M-$98,000$18.02M-$588,000
Depreciation & amortization$60,000$60,000$20,000$100,000$127,000$120,000$100,000$100,000
Stock-based compensation$254,000$419,000$385,000$385,000$523,000$574,000$770,000$815,000

Free plan shows the latest 8 periods; Pro shows all 18 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.